Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation

J. E. Panoff, J. Hurley, C. Takita, I. M. Reis, W. Zhao, V. Sujoy, C. R. Gomez, M. Jorda, Leonidas Koniaris, J. L. Wright

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

We assessed differences in locoregional outcome based on receptor status combinations in a cohort of stage II-III breast cancer patients treated with modern trimodality therapy. Medical records of 582 consecutively treated patients receiving post-mastectomy radiation (PMRT) between 1/1999 and 12/2009 were reviewed. Rate of local regional recurrence (LRR) was estimated by the method of cumulative incidence allowing for competing risks. The effect of prognostic factors was examined by Gray's test and by Fine and Gray's modeling approach. Median follow-up was 44.7 months. Five-year progression-free survival (PFS) was 73.9% and overall survival (OS) was 84%. The cumulative 5-year incidence of LRR as first site of failure was 6.2% (95% CI 4.2-8.7). Five-year cumulative incidence of LRR was 8.6 versus 4.4% for estrogen receptor (ER) negative versus ER positive (P = 0.017), 8.5 versus 3.4% for progesterone receptor (PR) negative versus PR positive (P = 0.011), and 1.7 versus 7.5% for HER2 positive (86% received trastuzamab) versus HER2 negative (P = 0.032). Five-year cumulative incidence of LRR was 11.8% for the triple negative subtype and 3.9% for other receptor combinations (P <0.001). Among patients whose disease is ER positive, 5-year LRR rate was 7.8 versus 3.4% for PR negative versus PR positive (P = 0.130). The prognostic value of the triple negative and HER2 negative subtypes was maintained on multivariate analysis. In the era of HER-2 targeted therapy, tumors that are HER-2 over expressing and are treated with trastuzumab have a very low rate of LRR. ER negative, PR negative, and triple negative status are associated with increased risk of LRR.

Original languageEnglish (US)
Pages (from-to)899-906
Number of pages8
JournalBreast Cancer Research and Treatment
Volume128
Issue number3
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Mastectomy
Progesterone Receptors
Radiation
Breast Neoplasms
Recurrence
Estrogen Receptors
Incidence
Therapeutics
Disease-Free Survival
Medical Records
Multivariate Analysis
Survival
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. / Panoff, J. E.; Hurley, J.; Takita, C.; Reis, I. M.; Zhao, W.; Sujoy, V.; Gomez, C. R.; Jorda, M.; Koniaris, Leonidas; Wright, J. L.

In: Breast Cancer Research and Treatment, Vol. 128, No. 3, 08.2011, p. 899-906.

Research output: Contribution to journalArticle

Panoff, J. E. ; Hurley, J. ; Takita, C. ; Reis, I. M. ; Zhao, W. ; Sujoy, V. ; Gomez, C. R. ; Jorda, M. ; Koniaris, Leonidas ; Wright, J. L. / Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. In: Breast Cancer Research and Treatment. 2011 ; Vol. 128, No. 3. pp. 899-906.
@article{528809c9390f4dbea3ce58a607580fe0,
title = "Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation",
abstract = "We assessed differences in locoregional outcome based on receptor status combinations in a cohort of stage II-III breast cancer patients treated with modern trimodality therapy. Medical records of 582 consecutively treated patients receiving post-mastectomy radiation (PMRT) between 1/1999 and 12/2009 were reviewed. Rate of local regional recurrence (LRR) was estimated by the method of cumulative incidence allowing for competing risks. The effect of prognostic factors was examined by Gray's test and by Fine and Gray's modeling approach. Median follow-up was 44.7 months. Five-year progression-free survival (PFS) was 73.9{\%} and overall survival (OS) was 84{\%}. The cumulative 5-year incidence of LRR as first site of failure was 6.2{\%} (95{\%} CI 4.2-8.7). Five-year cumulative incidence of LRR was 8.6 versus 4.4{\%} for estrogen receptor (ER) negative versus ER positive (P = 0.017), 8.5 versus 3.4{\%} for progesterone receptor (PR) negative versus PR positive (P = 0.011), and 1.7 versus 7.5{\%} for HER2 positive (86{\%} received trastuzamab) versus HER2 negative (P = 0.032). Five-year cumulative incidence of LRR was 11.8{\%} for the triple negative subtype and 3.9{\%} for other receptor combinations (P <0.001). Among patients whose disease is ER positive, 5-year LRR rate was 7.8 versus 3.4{\%} for PR negative versus PR positive (P = 0.130). The prognostic value of the triple negative and HER2 negative subtypes was maintained on multivariate analysis. In the era of HER-2 targeted therapy, tumors that are HER-2 over expressing and are treated with trastuzumab have a very low rate of LRR. ER negative, PR negative, and triple negative status are associated with increased risk of LRR.",
author = "Panoff, {J. E.} and J. Hurley and C. Takita and Reis, {I. M.} and W. Zhao and V. Sujoy and Gomez, {C. R.} and M. Jorda and Leonidas Koniaris and Wright, {J. L.}",
year = "2011",
month = "8",
doi = "10.1007/s10549-011-1495-1",
language = "English (US)",
volume = "128",
pages = "899--906",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation

AU - Panoff, J. E.

AU - Hurley, J.

AU - Takita, C.

AU - Reis, I. M.

AU - Zhao, W.

AU - Sujoy, V.

AU - Gomez, C. R.

AU - Jorda, M.

AU - Koniaris, Leonidas

AU - Wright, J. L.

PY - 2011/8

Y1 - 2011/8

N2 - We assessed differences in locoregional outcome based on receptor status combinations in a cohort of stage II-III breast cancer patients treated with modern trimodality therapy. Medical records of 582 consecutively treated patients receiving post-mastectomy radiation (PMRT) between 1/1999 and 12/2009 were reviewed. Rate of local regional recurrence (LRR) was estimated by the method of cumulative incidence allowing for competing risks. The effect of prognostic factors was examined by Gray's test and by Fine and Gray's modeling approach. Median follow-up was 44.7 months. Five-year progression-free survival (PFS) was 73.9% and overall survival (OS) was 84%. The cumulative 5-year incidence of LRR as first site of failure was 6.2% (95% CI 4.2-8.7). Five-year cumulative incidence of LRR was 8.6 versus 4.4% for estrogen receptor (ER) negative versus ER positive (P = 0.017), 8.5 versus 3.4% for progesterone receptor (PR) negative versus PR positive (P = 0.011), and 1.7 versus 7.5% for HER2 positive (86% received trastuzamab) versus HER2 negative (P = 0.032). Five-year cumulative incidence of LRR was 11.8% for the triple negative subtype and 3.9% for other receptor combinations (P <0.001). Among patients whose disease is ER positive, 5-year LRR rate was 7.8 versus 3.4% for PR negative versus PR positive (P = 0.130). The prognostic value of the triple negative and HER2 negative subtypes was maintained on multivariate analysis. In the era of HER-2 targeted therapy, tumors that are HER-2 over expressing and are treated with trastuzumab have a very low rate of LRR. ER negative, PR negative, and triple negative status are associated with increased risk of LRR.

AB - We assessed differences in locoregional outcome based on receptor status combinations in a cohort of stage II-III breast cancer patients treated with modern trimodality therapy. Medical records of 582 consecutively treated patients receiving post-mastectomy radiation (PMRT) between 1/1999 and 12/2009 were reviewed. Rate of local regional recurrence (LRR) was estimated by the method of cumulative incidence allowing for competing risks. The effect of prognostic factors was examined by Gray's test and by Fine and Gray's modeling approach. Median follow-up was 44.7 months. Five-year progression-free survival (PFS) was 73.9% and overall survival (OS) was 84%. The cumulative 5-year incidence of LRR as first site of failure was 6.2% (95% CI 4.2-8.7). Five-year cumulative incidence of LRR was 8.6 versus 4.4% for estrogen receptor (ER) negative versus ER positive (P = 0.017), 8.5 versus 3.4% for progesterone receptor (PR) negative versus PR positive (P = 0.011), and 1.7 versus 7.5% for HER2 positive (86% received trastuzamab) versus HER2 negative (P = 0.032). Five-year cumulative incidence of LRR was 11.8% for the triple negative subtype and 3.9% for other receptor combinations (P <0.001). Among patients whose disease is ER positive, 5-year LRR rate was 7.8 versus 3.4% for PR negative versus PR positive (P = 0.130). The prognostic value of the triple negative and HER2 negative subtypes was maintained on multivariate analysis. In the era of HER-2 targeted therapy, tumors that are HER-2 over expressing and are treated with trastuzumab have a very low rate of LRR. ER negative, PR negative, and triple negative status are associated with increased risk of LRR.

UR - http://www.scopus.com/inward/record.url?scp=79960845909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960845909&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1495-1

DO - 10.1007/s10549-011-1495-1

M3 - Article

C2 - 21475999

AN - SCOPUS:79960845909

VL - 128

SP - 899

EP - 906

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -